Skip to main content
. 2020 Jun 29;11(6):1583–1602. doi: 10.1093/advances/nmaa073

TABLE 4.

Overview of the findings associated with ketogenic therapy in patients with AD or mild cognitive impairment1

Effects First author Cognitive battery Mood/depression Efficacy in everyday behavior Blood ketone bodies concentrations AD protein and peptide concentrations in CSF Brain ketone uptake rCBF
Long-term Brandt (45) MMSE and MCS ↑ POMS-Bi (at wk 6) ∼ MDS-HC
Craft (46) ↑ t-tau, ∼ Aβ42 ↑ [11C] AcAc
Fortier (47) ∼ MMSE and MoCA,↑ Stroop,↑ RL/RI-16,↑ BVMT-R ↑ BHB ↑ Global brain CMRAcAc and CMRKetones∼ CMRGlu
Henderson (48) ε4− ADAS-Cog,↑ε4− ADCS-CGIC (day 45),↑ε4+ MMSE (day 104) ↑ BHB
Henderson (49) 2 ADAS-Cog↑ε4− ADAS-Cog
Krikorian (50) ∼ TMT, ↑ V-PAL ∼ GDS
Rebello (52) ε4−ADAS-Cog,3∼ TMT and Digit Symbol
Torosyan (54) ε4− rCBF in the left superior lateral temporal cortex
Acute Ota (51) ∼ WAIS-III, WMS-R, Stroop, TMT ↑ AcAc and BHB
Rebello (52) ε4− BHB3
Reger (53) ε4− ADAS-Cog, ∼ Stroop ↑ BHB
Torosyan (54) ε4− rCBF in dorsolateral prefrontal and temporal cortices
1

AcAc, acetoacetate; AD, Alzheimer disease; ADAS-Cog, Alzheimer's Disease Assessment Scale-Cognitive subscale (58); ADCS-CGIC, AD Cooperative Study–Clinical Global Impression of Change (76); APOE, apoE; Aβ42, amyloid β 42; BHB, serum β-hydroxybutyrate; BVMT-R, Brief Visuospatial Memory Test-Revised (62); CMR, cerebral metabolic rate; CSF, cerebrospinal fluid; GDS, Geriatric Depression Scale (73); Glu, glucose; MCS, Memory Composite Score; MDS-HC, Minimum Data Set for Home Care (75); MMSE, Mini-Mental State Exam (59); MoCA, Montreal Cognitive Assessment (60); POMS-Bi, Profile of Mood States Bipolar Scale (74); rCBF, regional cerebral blood flow; RL/RI-16, Rappel Libre/Rappel Indicé (64); Stroop, Stroop Color Word Interference (66); TMT, Trail Making Test (68); t-tau, total tau; V-PAL, Verbal Paired Associate Learning Test (63); WAIS-III, Wechsler Adult Intelligence Scale-3rd (77); WMS-R, Wechsler Memory Scale-Revised (78); ε4−, APOE ε4(−); ε4+, APOE ε4(+); ↑, improved; ∼, no change.

2

Homozygous carriers of the ε3 allele.

3

n = 1 participant only.